CD40L (human) (multimeric) (rec.) (Certified Serum Grade)
| Code | Size | Price |
|---|
| AG-40B-0010CSG-C100 | 100 ug | £1,427.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: CHO Cells
Regulatory Status: RUO
Target Species: Human
Shipping:
DRY ICE
Storage:
Short term storage:-20°C. Long term storage:-20°C.
Further Information
Alternate Names/Synonyms:
MultimericCD40L™; ACRP30headless:CD40L; ACRP30headless:CD154; ACRP30headless:TNFSF5; ADIPOQ-CD40L
Biological Activity:
Induces B cells activation (as demonstrated by dose-dependent upregulation of CD86) (ED50: <1ng/ml). B cell expansion online protocol available.
Concentration:
1mg/ml
EClass:
32160000
Endotoxin:
<0.01EU/ug purified protein (LAL test, Lonza).
Form (Short):
liquid
Formulation:
Liquid. Contains PBS.
Handling Advice:
Avoid freeze/thaw cycles. PBS containing at least 0. 1% BSA should be used for further dilutions.
Long Description:
Recombinant protein. Human CD40L (aa 116-261) is fused at the N-terminus to mouse ACRP30headless (aa 18-111) and a FLAG ®-tag. Induces B cells activation (as demonstrated by dose-dependent upregulation of CD86) (ED50: <1ng/ml). B cell expansion online protocol available. Source: CHO cells. Produced using certified serum/medium.*. Liquid. Contains PBS. MultimericCD40L? is a high-activity construct in which two trimeric CD40 ligands are artificially linked via the collagen domain of ACRP30. This construct very effectively simulates the natural membrane-assisted aggregation of CD40L in vivo. It provides a simple and equally potent alternative to [CD40L+enhancer] combinations. MultimericCD40L? has been shown to suppress alum-induced IL-1beta release and caspase-1 activation in a dose-, CD40- and time-dependent manner, without affecting BMDM viability. It also effectively suppressed the inflammasome function triggered by NLRP3 activators. The secretion of caspase-1 independent inflammatory mediators has been shown to be unaltered or even enhanced. MultimericCD40L? has been shown to be a potent tool for B cell expansion. It also has big potential as a growth factor for tumor-infiltrating lymphocytes (TILs), which have been shown to be important for T cell therapy.
Molecular Weight:
~35-40kDa (SDS-PAGE)
NCBI, Uniprot Number:
P29965
Package Type:
Plastic Vial
Product Description:
MultimericCD40L™ is a high-activity construct in which two trimeric CD40 ligands are artificially linked via the collagen domain of ACRP30. This construct very effectively simulates the natural membrane-assisted aggregation of CD40L in vivo. It provides a simple and equally potent alternative to [CD40L+enhancer] combinations. MultimericCD40L™ has been shown to suppress alum-induced IL-1beta release and caspase-1 activation in a dose-, CD40- and time-dependent manner, without affecting BMDM viability. It also effectively suppressed the inflammasome function triggered by NLRP3 activators. The secretion of caspase-1 independent inflammatory mediators has been shown to be unaltered or even enhanced. MultimericCD40L™ has been shown to be a potent tool for B cell expansion. It also has big potential as a growth factor for tumor-infiltrating lymphocytes (TILs), which have been shown to be important for T cell therapy.
Purity:
>95% (SDS-PAGE)
Sequence:
Human CD40L (aa 116-261) is fused at the N-terminus to mouse ACRP30headless (aa 18-111) and a FLAG ®-tag.
Source / Host:
CHO cells. Produced using certified serum/medium.*
Specificity:
Binds to human CD40.
TAGs:
FLAG
Transportation:
Non-hazardous
UNSPSC Number:
12352202
Use & Stability:
Stable for at least 6 months after receipt when stored at -20°C.Working aliquots are stable for up to 3 months when stored at -20°C.
References
IgG subclass switch capacity is low in switched and in IgM-only, but high in IgD+IgM+, post-germinal center (CD27+) human B cells: C. Werner-Favre, et al.; Eur. J. Immunol. 31, 243 (2001) | Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex: N. Holler, et al.; Mol. Cell. Biol. 23, 1428 (2003) | Impaired CD40L signaling is a cause of defective IL-12 and TNF-alpha production in Sezary syndrome: circumvention by hexameric soluble CD40L: L.E. French, et al.; Blood 105, 219 (2005) | Cysteine-rich Domain 1 of CD40 Mediates Receptor Self-assembly: C.R. Smulski, et al.; J. Biol. Chem. 288, 10914 (2013) | Sensitive, multiplex and direct quantification of RNA sequences using a modified RASL assay: H.B. Larman, et al.; Nucl. Acids Res. 42, 9146 (2014) | CD4+ T Cell-derived IL-21 and deprivation of CD40 signaling favor the In Vivo development of granzyme B-expressing regulatory B cells in HIV patients: C. Kaltenmeier, et al.; J. Immunol. 194, 3768 (2015) | Lenalidomide potentiates CD4+ CD25+ Treg-related suppression of lymphoma B-cell proliferation: M.A. Grygorowicz, et al.; Clin. Exp. Med.~17, 193 (2017) | CRISPR/Cas9 Screens Reveal Multiple Layers of B cell CD40 Regulation: Ch. Jiang, et al.; Cell Rep. 28, 1307 (2019) | Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes: J. Racle, et al.; Nat. Biotech. 37, 1283 (2019) | Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes: C. Chong, et al.; Nat. Commun. 11, 1293 (2020) | Biogenesis of HLA Ligand Presentation in Immune Cells Upon Activation Reveals Changes in Peptide Length Preference: F. Marino, et al.; Front. Immunol. 11, 1981 (2020) | Detection of alloreactive T cells from cryopreserved human peripheral blood mononuclear cells: N. Tanimine, et al.; J. Immunol. Meth. 491, 112987 (2021) | Sensitive identification of neoantigens and cognate TCRs in human solid tumors: M. Arnaud, et al.; Nat. Biotechnol. 40, 656 (2022)